TRML Earnings
Tourmaline Bio Inc
$
0.000
Earning Analysis
Welcome to our in-depth analysis of Tourmaline Bio Inc(TRML) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Tourmaline Bio Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency:
Actual
Estimate
Surprise Analysis
| FY2024Q1 | 2024-05-13 | - | -0.68 | -0.55 | +19.12 | - | - | - | -0.41 | +3.72 |
| FY2023Q4 | 2024-03-19 | - | -0.75 | -0.81 | -8.00 | - | - | - | +0.80 | -40.49 |
| FY2023Q3 | 2023-11-14 | - | -0.94 | -1.64 | -74.47 | - | - | - | +0.74 | +8.28 |
| - | 2022-11-10 | - | -0.42 | -0.46 | -9.52 | - | - | - | +6.99 | +2.80 |
| - | 2022-08-15 | - | -0.46 | -0.44 | +4.35 | - | - | - | - | -15.88 |
| - | 2022-05-12 | - | -0.35 | -0.45 | -28.57 | - | - | - | -5.25 | +20.83 |
| - | 2022-03-17 | - | -0.35 | -0.31 | +11.43 | - | - | - | +2.05 | +12.95 |
| - | 2021-11-12 | - | -0.28 | -0.32 | -14.29 | - | - | - | - | -10.51 |
| - | 2021-08-12 | - | -0.22 | -0.41 | -86.36 | - | - | - | -2.34 | -6.66 |
| - | 2021-06-14 | - | -1.79 | -1.30 | +27.37 | - | - | - | - | -2.98 |
TRML Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Tourmaline Bio Inc reported performance for FY2024Q1, announced on 2024-05-13. The company achieved an EPS of -0.55, compared to analyst estimates of -0.68 by 19.12% . Revenue for the quarter reached 0.00 compared to expectations of 0.00 by % .
The stock price reacted with a -0.41% one-day change and a 3.72% five-day change following the earnings release. These movements reflect market reaction in Tourmaline Bio Inc growth trajectory and strategic initiatives.
TRML Earnings Forecast
Looking ahead, Tourmaline Bio Inc(TRML) remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of and an EPS of -0.98.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 25%, while EPS estimates have been Revise Upward by 12.59%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 12.5% . These revisions correlate with a 122.23% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Tourmaline Bio Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between TRML's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+25%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+12.59%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
+12.5%
In Past 3 Month
Stock Price
Go Up
+122.23%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:7.50M
--
EPS Estimate-Annual FY 2025:-3.80
—
Stock Price47.98
TRML Revenue and EPS Performance: A Historical Perspective
Tourmaline Bio Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2024Q1 (2024-05-13,):
EPS: -0.55 (Actual) vs.-0.68 (Estimate) (19.12%)
Revenue: 0.00 (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: -0.41%(1-Day), 3.72%(5-Day)
FY2023Q4 (2024-03-19,):
EPS: -0.81 (Actual) vs.-0.75 (Estimate) (-8.00%)
Revenue: 0.00 (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: 0.80%(1-Day), -40.49%(5-Day)
FY2023Q3 (2023-11-14,):
EPS: -1.64 (Actual) vs.-0.94 (Estimate) (-74.47%)
Revenue: 0.00 (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: 0.74%(1-Day), 8.28%(5-Day)
Earnings Reaction
The chart below shows how TRML performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TRML sees a +0.48% change in stock price 10 days leading up to the earnings, and a -7.50% change 10 days following the report. On the earnings day itself, the stock moves by +0.26%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in MAR/2024, the stock changed -0.14% on the day following the earnings release and then changed by -5.12% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
No Data
People Also Watch
DCTH
Delcath Systems Inc
9.830
USD
+4.57%
MLYS
Mineralys Therapeutics Inc
40.860
USD
-0.63%
AROW
Arrow Financial Corp
27.890
USD
+2.84%
BWMN
Bowman Consulting Group Ltd
43.290
USD
+0.05%
CLCO
Cool Company Ltd
9.650
USD
0.00%
ARCT
Arcturus Therapeutics Holdings Inc
9.970
USD
+3.53%
TWFG
TWFG Inc
24.360
USD
-0.08%
GCBC
Greene County Bancorp Inc
21.950
USD
+0.14%
AIP
Arteris Inc
13.610
USD
+2.25%
FAQ
What were the key highlights of TRML’s latest earnings report for FY2024Q1?
TRML reported its FY2024Q1 earnings on 2024-05-13, showcasing a revenue of 0.00 against an estimate of 0.00, resulting in a 0% surprise. The EPS was -0.55, surpassing the expected -0.68 by 19.12% . The stock experienced a -0.41% price change on the earnings day and a 3.72% change over the next five days, reflecting market reactions to the results.
How did TRML’s stock price react after the FY2024Q1 earnings release?
What are the revenue and EPS estimates for TRML for undefined?
How does TRML’s stock price correlate with earnings forecast revisions?
What should investors expect from TRML’s next earnings report?